<HashMap><database>GEO</database><scores/><additional><omics_type>Transcriptomics</omics_type><species>Mus musculus</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE333360</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Distinct neuroinflammatory effects of individual chemotherapeutics shape chemotherapy-induced peripheral neuropathy in a novel mouse model of CVAD combination regimen.</name><description>Chemotherapy-induced peripheral neuropathy (CIPN) is a common, dose-limiting toxicity of cancer treatment for which no disease-modifying therapies exist. Vincristine-induced neuropathy has been linked to neuroimmune activation and interleukin-1 (IL-1) signaling; however, vincristine is almost exclusively administered as part of combination chemotherapy regimens, where the relevance of IL-1–dependent mechanisms remains poorly defined. Here we investigate the role of IL-1 receptor (IL-1R) signaling in neuropathy induced by vincristine alone and by the standard CVAD regimen (cyclophosphamide, vincristine, doxorubicin and dexamethasone) in male C57BL6/J mice. IL-1R blockade with the clinically approved antagonist anakinra prevented vincristine-induced mechanical hypersensitivity and attenuated established vincristine-induced peripheral neuropathy, without adverse effects on motor function, hematological parameters or body weight. Additionally, we established a novel CVAD-induced neuropathy model and demonstrate that anakinra partially attenuated CVAD-induced mechanical hypersensitivity and preserved motor function without exacerbating systemic toxicity. Dissection of individual CVAD components identified vincristine as the dominant driver of grip strength decline and IL-1–dependent neuroinflammatory signaling, whereas cyclophosphamide and doxorubicin contributed to sensory hypersensitivity through largely IL-1R–independent mechanisms, and dexamethasone did not induce sensory neuropathy. Immunohistochemistry and transcriptome profiling of peripheral nervous tissue revealed distinct, time-dependent and agent-specific neuroimmune responses with distinct inflammatory and immunosuppressive effects shaping the net CVAD neuroinflammatory phenotype. Together, these findings redefine CIPN as an emergent property of combination chemotherapy and establish IL-1R signaling as a context-dependent therapeutic target with translational relevance.</description><dates><publication>2026/05/31</publication></dates><accession>GSE333360</accession><cross_references><GSM>GSM9761484</GSM><GSM>GSM9761485</GSM><GSM>GSM9761483</GSM><GSM>GSM9761503</GSM><GSM>GSM9761504</GSM><GSM>GSM9761501</GSM><GSM>GSM9761502</GSM><GSM>GSM9761488</GSM><GSM>GSM9761500</GSM><GSM>GSM9761489</GSM><GSM>GSM9761486</GSM><GSM>GSM9761487</GSM><GSM>GSM9761495</GSM><GSM>GSM9761496</GSM><GSM>GSM9761493</GSM><GSM>GSM9761494</GSM><GSM>GSM9761491</GSM><GSM>GSM9761492</GSM><GSM>GSM9761490</GSM><GSM>GSM9761512</GSM><GSM>GSM9761510</GSM><GSM>GSM9761499</GSM><GSM>GSM9761511</GSM><GSM>GSM9761497</GSM><GSM>GSM9761498</GSM><GSM>GSM9761509</GSM><GSM>GSM9761507</GSM><GSM>GSM9761508</GSM><GSM>GSM9761505</GSM><GSM>GSM9761506</GSM><GPL>24247</GPL><GSE>333360</GSE><taxon>Mus musculus</taxon></cross_references></HashMap>